View Post

mRNA-Based Influenza and COVID-19 Combo Vaccine Candidate Launches Study

In COVID-19, Latest News by Precision Vaccinations

Global leaders in vaccine innovation today announced the advancement of an mRNA-based vaccine candidate preventing both influenza and COVID-19 to a Phase 1 clinical trial.
The Pfizer Inc. and BioNTech SE vaccine candidate aims to address these severe respiratory diseases with one vaccine.
The vaccine candidate combines Pfizer's quadrivalent modRNA-based influenza vaccine candidate, qIRV (22/23), which is currently in Phase 3 clinical development, and Pfizer and BioNTech's authorized Omicron-adapted bivalent COVID-19 BNT162b2 (Original/Omicron BA.4/BA.5) vaccine.

View Post

mRNA-Based Influenza and COVID-19 Combo Vaccine Candidate Launches Study

In Influenza Vaccine News by Influenza Vaccine

Global leaders in vaccine innovation today announced the advancement of an mRNA-based vaccine candidate preventing both influenza and COVID-19 to a Phase 1 clinical trial.
The Pfizer Inc. and BioNTech SE vaccine candidate aims to address these severe respiratory diseases with one vaccine.
The vaccine candidate combines Pfizer's quadrivalent modRNA-based influenza vaccine candidate, qIRV (22/23), which is currently in Phase 3 clinical development, and Pfizer and BioNTech's authorized Omicron-adapted bivalent COVID-19 BNT162b2 (Original/Omicron BA.4/BA.5) vaccine.